Eesti - eesti - Ravimiamet

virbac - permetriin+fiproniil - täpilahus - 240mg+26,8mg 0.44ml 0.44ml 60tk; 240mg+26,8mg 0.44ml 0.44ml 1tk; 240mg+26,8mg 0.44ml 0.44ml 4tk

Eesti - eesti - Ravimiamet

virbac - permetriin+fiproniil - täpilahus - 2400mg+268mg 4.4ml 4.4ml 24tk; 2400mg+268mg 4.4ml 4.4ml 60tk; 2400mg+268mg 4.4ml 4.4ml 4tk; 2400mg+268mg 4.4ml 4.4ml 1tk

Eesti - eesti - Ravimiamet

virbac - permetriin+fiproniil - täpilahus - 600mg+67mg 1.1ml 1.1ml 60tk; 600mg+67mg 1.1ml 1.1ml 4tk; 600mg+67mg 1.1ml 1.1ml 24tk

Eesti - eesti - Ravimiamet

virbac - permetriin+fiproniil - täpilahus - 3600mg+402mg 6.6ml 6.6ml 1tk; 3600mg+402mg 6.6ml 6.6ml 60tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - fiproniil - täpilahus - 67mg 0.67ml 0.67ml 6tk; 67mg 0.67ml 0.67ml 20tk; 67mg 0.67ml 0.67ml 10tk; 67mg 0.67ml 0.67ml 3tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - fiproniil - täpilahus - 50mg 0.5ml 0.5ml 6tk; 50mg 0.5ml 0.5ml 20tk; 50mg 0.5ml 0.5ml 1tk; 50mg 0.5ml 0.5ml 3tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - fiproniil - täpilahus - 402mg 4.02ml 4.02ml 6tk; 402mg 4.02ml 4.02ml 10tk; 402mg 4.02ml 4.02ml 3tk; 402mg 4.02ml 4.02ml 20tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - fiproniil - täpilahus - 268mg 2.68ml 2.68ml 20tk; 268mg 2.68ml 2.68ml 3tk; 268mg 2.68ml 2.68ml 1tk; 268mg 2.68ml 2.68ml 10tk; 268mg 2.68ml 2.68ml 6tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - fiproniil - täpilahus - 134mg 1.34ml 1.34ml 10tk; 134mg 1.34ml 1.34ml 1tk; 134mg 1.34ml 1.34ml 20tk; 134mg 1.34ml 1.34ml 3tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - atezolüsumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastilised ained - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähi pärast eelnevat keemiaravi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähi pärast eelnevat keemiaravi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.